SG87145A1 - Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems - Google Patents
Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systemsInfo
- Publication number
- SG87145A1 SG87145A1 SG200004340A SG200004340A SG87145A1 SG 87145 A1 SG87145 A1 SG 87145A1 SG 200004340 A SG200004340 A SG 200004340A SG 200004340 A SG200004340 A SG 200004340A SG 87145 A1 SG87145 A1 SG 87145A1
- Authority
- SG
- Singapore
- Prior art keywords
- making
- heterocyclic ring
- ring systems
- lipoxygenase inhibitors
- varied
- Prior art date
Links
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrane Compounds (AREA)
- Pyridine Compounds (AREA)
- Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15161099P | 1999-08-31 | 1999-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG87145A1 true SG87145A1 (en) | 2002-03-19 |
Family
ID=22539510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200004340A SG87145A1 (en) | 1999-08-31 | 2000-08-01 | Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
Country Status (33)
| Country | Link |
|---|---|
| EP (1) | EP1081144A3 (cs) |
| JP (1) | JP2001106686A (cs) |
| KR (1) | KR20010050274A (cs) |
| CN (1) | CN1286251A (cs) |
| AP (1) | AP2000001909A0 (cs) |
| AR (1) | AR022650A1 (cs) |
| AU (1) | AU5370200A (cs) |
| BG (1) | BG104730A (cs) |
| BR (1) | BR0003888A (cs) |
| CA (1) | CA2316748A1 (cs) |
| CO (1) | CO5180623A1 (cs) |
| CZ (1) | CZ20003159A3 (cs) |
| EA (1) | EA200000803A3 (cs) |
| EE (1) | EE200000513A (cs) |
| GT (1) | GT200000144A (cs) |
| HR (1) | HRP20000565A2 (cs) |
| HU (1) | HUP0003437A3 (cs) |
| ID (1) | ID27128A (cs) |
| IL (1) | IL138089A0 (cs) |
| IS (1) | IS5604A (cs) |
| MA (1) | MA26750A1 (cs) |
| NO (1) | NO20004312L (cs) |
| NZ (1) | NZ506633A (cs) |
| OA (1) | OA11451A (cs) |
| PA (1) | PA8499601A1 (cs) |
| PE (1) | PE20010523A1 (cs) |
| PL (1) | PL342280A1 (cs) |
| SG (1) | SG87145A1 (cs) |
| SK (1) | SK12862000A3 (cs) |
| SV (1) | SV2002000160A (cs) |
| TN (1) | TNSN00176A1 (cs) |
| TR (1) | TR200002530A2 (cs) |
| UY (1) | UY26315A1 (cs) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1627644A4 (en) * | 2003-05-23 | 2012-01-18 | Hisamitsu Pharmaceutical Co | PREPARATION FOR EXTERNAL PERCUTANEOUS ADMINISTRATION WITH AN NON-TEROIDAL INFLAMMATORY MEDICAMENT AND AN INTERLEUKIN 1A PRODUCTION INHIBITOR |
| EP1834953A1 (en) * | 2006-03-14 | 2007-09-19 | Ranbaxy Laboratories Limited | Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors |
| CN103980312B (zh) * | 2014-05-27 | 2016-09-07 | 广州大学 | 一种n杂环双膦配体及其合成方法 |
| WO2025038927A1 (en) * | 2023-08-16 | 2025-02-20 | Raythera, Inc. | Modulators of tnf alpha activity and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996011911A1 (en) * | 1994-10-18 | 1996-04-25 | Pfizer Inc. | 5-lipoxygenase inhibitors |
-
2000
- 2000-08-01 SG SG200004340A patent/SG87145A1/en unknown
- 2000-08-10 PA PA20008499601A patent/PA8499601A1/es unknown
- 2000-08-11 CO CO00060138A patent/CO5180623A1/es not_active Application Discontinuation
- 2000-08-17 EP EP00307046A patent/EP1081144A3/en not_active Withdrawn
- 2000-08-18 OA OA1200000224A patent/OA11451A/en unknown
- 2000-08-24 IL IL13808900A patent/IL138089A0/xx unknown
- 2000-08-24 TN TNTNSN00176A patent/TNSN00176A1/fr unknown
- 2000-08-25 IS IS5604A patent/IS5604A/is unknown
- 2000-08-25 SK SK1286-2000A patent/SK12862000A3/sk unknown
- 2000-08-28 UY UY26315A patent/UY26315A1/es not_active Application Discontinuation
- 2000-08-28 ID IDP20000710A patent/ID27128A/id unknown
- 2000-08-29 CA CA002316748A patent/CA2316748A1/en not_active Abandoned
- 2000-08-29 PE PE2000000886A patent/PE20010523A1/es not_active Application Discontinuation
- 2000-08-29 AU AU53702/00A patent/AU5370200A/en not_active Abandoned
- 2000-08-29 GT GT200000144A patent/GT200000144A/es unknown
- 2000-08-29 AR ARP000104489A patent/AR022650A1/es not_active Application Discontinuation
- 2000-08-29 BG BG104730A patent/BG104730A/xx unknown
- 2000-08-30 MA MA26053A patent/MA26750A1/fr unknown
- 2000-08-30 HU HU0003437A patent/HUP0003437A3/hu unknown
- 2000-08-30 CZ CZ20003159A patent/CZ20003159A3/cs unknown
- 2000-08-30 CN CN00126409A patent/CN1286251A/zh active Pending
- 2000-08-30 KR KR1020000050877A patent/KR20010050274A/ko not_active Abandoned
- 2000-08-30 NZ NZ506633A patent/NZ506633A/en unknown
- 2000-08-30 HR HR20000565A patent/HRP20000565A2/hr not_active Application Discontinuation
- 2000-08-30 NO NO20004312A patent/NO20004312L/no not_active Application Discontinuation
- 2000-08-30 SV SV2000000160A patent/SV2002000160A/es unknown
- 2000-08-30 BR BR0003888-1A patent/BR0003888A/pt not_active IP Right Cessation
- 2000-08-31 EE EEP200000513A patent/EE200000513A/xx unknown
- 2000-08-31 EA EA200000803A patent/EA200000803A3/ru unknown
- 2000-08-31 JP JP2000262200A patent/JP2001106686A/ja active Pending
- 2000-08-31 AP APAP/P/2000/001909A patent/AP2000001909A0/en unknown
- 2000-08-31 TR TR2000/02530A patent/TR200002530A2/xx unknown
- 2000-08-31 PL PL00342280A patent/PL342280A1/xx not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996011911A1 (en) * | 1994-10-18 | 1996-04-25 | Pfizer Inc. | 5-lipoxygenase inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB9900416D0 (en) | Inhibitors | |
| AU6895801A (en) | Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv | |
| EP1237624A4 (en) | DEVICE FOR INHIBITING CELL PROLIFERATION | |
| GB9929973D0 (en) | Heterocyclic compounds | |
| IL145065A0 (en) | Method for inhibiting angiogenesis | |
| AP2002002413A0 (en) | Heterocyclic compounds inhibiting angiogenesi | |
| GB9924522D0 (en) | Enzyme inhibitors | |
| EP1153022A4 (en) | PROTEASE INHIBITORS | |
| SG87145A1 (en) | Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems | |
| HU9902691D0 (en) | Process for re-esterification of alfa-keto-carboxylic-acid-esters | |
| HUP0202530A3 (en) | Method for the production of phosphonomethylglycin | |
| SG87146A1 (en) | Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems | |
| HU0003438D0 (en) | Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems | |
| MX225445B (es) | Metodo y produccion de n-fosfonometilglicina. | |
| HUP0103002A3 (en) | New process for obtaining 17betha-(n-terc-butylcarbamoyl)-3-one-4-aza-steroids | |
| HUP0000366A3 (en) | Process for producing heterocyclic compounds | |
| IL150128A0 (en) | Substituted bisindolymaleimides for the inhibition of cell proliferation | |
| AU5454600A (en) | Process for the isolation of rufomycin factors | |
| HU9904385D0 (en) | Method for akkumulator change | |
| GB9926102D0 (en) | An improved metalworking process | |
| GB9929341D0 (en) | Inhibitors | |
| GB9900413D0 (en) | Inhibitors | |
| GB9917294D0 (en) | Inhibitors | |
| GB9929340D0 (en) | Inhibitors | |
| HU9903281D0 (en) | Method for recycling of grogs |